CCRM Nordic appoints Dr. Anna Falk as Chief Scientific Officer

CCRM Nordic, a leading organization in the field of regenerative medicine, announce the appointment of Dr. Anna Falk as Chief Scientific Officer, marking a significant milestone in the organization’s mission to further strengthening the field of advanced therapy medicinal products (ATMPs). With a distinguished career characterized by groundbreaking contributions to cell and gene therapy research, Anna brings a wealth of knowledge and experience to CCRM Nordic.

Anna’s career spans decades, marked by significant achievements in regenerative medicine. Her pioneering work has been pivotal in advancing our understanding of regenerative medicine. With a rich portfolio of publications and collaborative in the ATMP sector, Anna has been at the forefront of developing innovative therapies that promise to transform patient care.

“Anna brings an impressive track record in regenerative medicine. Her visionary leadership will be pivotal in driving forward our ambitious initiatives, particularly as we expand our GMP laboratories and enhance our support for the life sciences ecosystem”, says Fredrik Wessberg, Chief Executive Officer of CCRM Nordic.

About CCRM Nordic:

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs.

About CCRM:

CCRM is a global, public-private partnership headquartered in Canada, established with seed funding provided by the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM is hosted by the University of Toronto. Visit at ccrm.ca